CHU Brest
- Address
- lock Available on a paid plan
CHU Brest - Oncology and Prostate Cancer Research
CHU Brest is a leading academic medical center engaged in advanced oncology research, with particular expertise in genitourinary malignancies. The center participates in innovative clinical trials exploring novel therapeutic approaches for patients with advanced prostate cancer, focusing on combination therapies and emerging anti-androgen strategies.
- Metastatic castration-resistant prostate cancer treatment optimization
- Novel androgen receptor pathway inhibitor combinations
- Phase 1 and Phase 2 dose-finding and efficacy studies in oncology
The research team at CHU Brest specializes in evaluating second generation anti-androgens and their combinations with investigational agents. Their work encompasses comprehensive safety and tolerability assessments, determination of recommended Phase 2 combination doses, and evaluation of anti-tumor activity in patients with metastatic castration-resistant prostate cancer. This commitment to precision oncology trials positions the center at the forefront of advancing treatment options for patients with advanced urological cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU Brest
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 1/2 Evaluation of EPI-7386 and Enzalutamide Combination Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | Essa Pharma Inc. | Phase I | Not Recruiting | Jun 2024 | Oct 2024 |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Enzalutamide | 1 | Unknown | 2024-06-12 | 2024-06-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.